Global perspective Human stories

Kenya: UNAIDS welcomes High Court judgment on anti-counterfeit law

UNAIDS Executive Director Michel Sidibé.
UNAIDS/B. Hamilton
UNAIDS Executive Director Michel Sidibé.

Kenya: UNAIDS welcomes High Court judgment on anti-counterfeit law

The lead United Nations agency dealing with the global HIV/AIDS response commended today the High Court of Kenya for a ruling on an anti-counterfeit law that will safeguard access to affordable generic medicines.

“A vast majority of people in Kenya rely on quality generic drugs for their daily survival. Through this important ruling, the High Court of Kenya has upheld a fundamental element of the right to health,” said UNAIDS’ Executive Director, Michel Sidibé, in a press statement.

“This decision will set an important precedent for ensuring access to life-saving drugs around the world,” he added.

According to UNAIDS, the High Court found that the definition of ‘anti-counterfeit’ within the 2008 Anti-Counterfeit Act was too broad, with the judge involved explaining in her ruling that “the Act is vague and could undermine access to affordable generic medicines since the Act had failed to clearly distinguish between counterfeit and generic medicines.”

The High Court called on Kenya’s Parliament to review the Act and remove ambiguities that could result in arbitrary seizures of generic medicines under the pretext of fighting counterfeit drugs. The judgment also stated that intellectual property rights should not override the right to life and health.

“We must have both generic drugs and strong anti-counterfeit laws,” Mr Sidibé said. “Generic drugs give more people access to life-saving treatment, while anti-counterfeit laws keep people safe.”

Kenya’s national HIV treatment programme relies heavily on access to generic antiretroviral medicines. At the end of 2011, about 1.6 million people in Kenya were living with HIV. An estimated 743,000 Kenyans are eligible for antiretroviral treatment, of whom 539,000 are currently receiving it.

In low- and middle-income countries more than 80 per cent of the antiretroviral drugs used by the 6.6 million people on HIV treatment come from generic manufacturers. Nearly eight million additional people living with HIV were eligible for treatment at the end of 2010.